ISSN: 2278-0238

Revista internacional de investigación y desarrollo en farmacia y ciencias biológicas

Acceso abierto

Nuestro grupo organiza más de 3000 Series de conferencias Eventos cada año en EE. UU., Europa y América. Asia con el apoyo de 1.000 sociedades científicas más y publica más de 700 Acceso abierto Revistas que contienen más de 50.000 personalidades eminentes, científicos de renombre como miembros del consejo editorial.

Revistas de acceso abierto que ganan más lectores y citas
700 revistas y 15 000 000 de lectores Cada revista obtiene más de 25 000 lectores

Abstracto

ICUed COVID-19 Patients with Hepatic Problems during the Third Wave of Coronavirus in Egypt

Alzhraa M. Fahmy, Marwa O. Elgendy, Ahmed M. Khalaf, Mona A. Abdelrahman, Ahmed O. El-Gendy

<p><strong>Background: </strong>The pandemic infection of COVID-19 virus is mostly a respiratory infection that has recently begun
to harm other vital organs, including the heart, kidney and liver.</p>
<p>Aim of work: The purpose of this study was to investigate the hepatic complications of COVID-19 patients and the
risks of being admitted to the ICU or dying.</p>
<p><strong>Methodology: </strong>The study included 200 COVID-19 infected Egyptian individuals who had virological symptoms and were tracked until they recovered or died; classified into six parts: co-morbidities (hypertension &amp; diabetes), experienced symptoms of COVID-19, laboratory findings (ALT enzyme level, AST enzyme level, Albumin), complications during
hospitalization, treatment protocol used and the survival outcomes.</p>
<p><strong>Results and Conclusion:</strong> It was recorded that older people and those with higher blood sugar levels have a higher risk of developing liver-associated COVID-19 disorders. Also, the majority of individuals who developed liver complications in the course of the infection experienced a high mortality rate. Patients with diabetes, hypertension or hepatic disease are at high risk to be admitted into ICU or to die. So, it is important to pay attention to these problems in the diagnosis and treatment of COVID-19 to develop a suitable individualized treatment protocol. There was a correlation between mortality in COVID 19 patients and both high blood sugar levels and high liver enzymes levels. It can be attributed to the diabetes and liver disease correlation as every disease may be the complication to the other, also, COVID 19 can lead to blood sugar level rise in addition to liver enzymes (ALT-AST) levels. Also, there was
another suggestion that COVID19 may affect liver and so the chronic liver disease patients.</p>